|
注册号: Registration number: |
ChiCTR2500111186 |
|
最近更新日期: Date of Last Refreshed on: |
2025-10-27 17:49:55 |
|
注册时间: Date of Registration: |
2025-10-27 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
HTO与HTO联合软骨修复治疗内侧间室膝关节炎疗效对比研究 |
|
Public title: |
Comparative Study on Efficacy of HTO versus HTO Combined with Cartilage Repair in the Treatment of Medial Compartment Knee Osteoarthritis |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
HTO与HTO联合软骨修复治疗内侧间室膝关节炎疗效对比研究 |
|
Scientific title: |
Comparative Study on Efficacy of HTO versus HTO Combined with Cartilage Repair in the Treatment of Medial Compartment Knee Osteoarthritis |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
盛世豪 |
研究负责人: |
陈晓 |
|
Applicant: |
Shihao Sheng |
Study leader: |
Xiao Chen |
|
申请注册联系人电话: Applicant telephone: |
+86 153 0180 3753 |
研究负责人电话:
Study leader's |
+86 135 6466 1943 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
doctorshengshihao@163.com |
研究负责人电子邮件: Study leader's E-mail: |
sirchenxiao@126.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
上海市杨浦区控江路1665号 |
研究负责人通讯地址: |
上海市杨浦区控江路1665号 |
|
Applicant address: |
1665 Kongjiang Road, Yangpu District, Shanghai |
Study leader's address: |
1665 Kongjiang Road, Yangpu District, Shanghai |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
上海交通大学医学院附属新华医院 |
||
|
Applicant's institution: |
Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine |
||
|
研究负责人所在单位: |
上海交通大学医学院附属新华医院 |
||
|
Affiliation of the Leader: |
Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
XHEC-C-2025-151-2 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
上海交通大学医学院附属新华医院医学伦理委员会 |
||
|
Name of the ethic committee: |
Xinhua Hospital Affiliated to Shanghai Jiaotong [niversity School of Medicine |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2025-07-23 00:00:00 | ||
|
伦理委员会联系人: |
施敏 |
||
|
Contact Name of the ethic committee: |
Min Shi |
||
|
伦理委员会联系地址: |
上海市杨浦区控江路1665号 |
||
|
Contact Address of the ethic committee: |
1665 Kongjiang Road, Yangpu District, Shanghai |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 21 2507 6143 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
上海交通大学医学院附属新华医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
上海市杨浦区控江路1665号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
1665 Kongjiang Road, Yangpu District, Shanghai |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
上海浩铱医疗器械有限公司 |
||||||||||||||||||||||
|
Source(s) of funding: |
Shanghai Hao Yi Medical Equipment Co., Ltd. |
||||||||||||||||||||||
|
研究疾病: |
骨关节炎 |
||||||||||||||||||||||
|
Target disease: |
Osteoarthritis |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
探索性研究/预试验 | ||||||||||||||||||||||
|
Study phase: |
0 |
||||||||||||||||||||||
|
研究设计: |
随机平行对照 |
||||||||||||||||||||||
|
Study design: |
Parallel |
||||||||||||||||||||||
|
研究目的: |
主要目的:比较单独接受截骨术与同时接受胶原蛋白诱导自体软骨成形术(ACIC)对内翻畸形的内侧骨关节炎患者之间的疗效对比,包括VAS评分、Lysholm评分、Tegner活动水平量表、IKDC评分、MRI下软骨修复组织(MOCART)评分、关节镜下国际软骨修复协会(ICRS)分级。 次要目的:比较单独接受截骨术与同时接受胶原蛋白诱导自体软骨成形术(ACIC)对内翻畸形的内侧骨关节炎患者之间并发症发生率、再手术率和总治疗费用。 |
||||||||||||||||||||||
|
Objectives of Study: |
Primary Objective: To compare the efficacy between patients with medial osteoarthritis and varus deformity undergoing osteotomy alone versus those undergoing osteotomy combined with Autologous Collagen-Induced Chondrogenesis (ACIC). The comparison will include assessments of VAS score, Lysholm score, Tegner activity level scale, IKDC score, MRI observation of cartilage repair tissue (MOCART) score, and arthroscopic International Cartilage Repair Society (ICRS) grade. Secondary Objective: To compare the complication rate, reoperation rate, and total treatment costs between patients with medial osteoarthritis and varus deformity undergoing osteotomy alone versus those undergoing osteotomy combined with Autologous Collagen-Induced Chondrogenesis (ACIC). |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
|||||||||||||||||||||||
|
Inclusion criteria |
|||||||||||||||||||||||
|
排除标准: |
1.严重内侧间室关节损伤(Ahlback Ⅱ级或更高)的患者 2.伴有髌股关节病及炎症性疾病的患者 3.关节活动度<120 °或屈曲挛缩>5 °的患者 4.BMI>30 kg/m^2的患者 5.无法耐受磁共振成像(MRI)扫描的患者 6.无法回答主观问卷或精神上不适合提供知情同意的患者 7.身体基础条件无法耐受手术的患者 |
||||||||||||||||||||||
|
Exclusion criteria: |
1. Patients with severe medial compartment joint damage (Ahlbäck grade II or higher). 2. Patients with concomitant patellofemoral osteoarthritis or inflammatory joint disease. 3. Patients with a range of motion <120° or flexion contracture >5°. 4. Patients with a BMI >30 kg/m². 5. Patients unable to tolerate magnetic resonance imaging (MRI) scans. 6. Patients unable to complete subjective questionnaires or mentally unfit to provide informed consent. 7. Patients whose general medical condition precludes tolerance for surgery. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2025-11-01 00:00:00至 To 2026-12-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2025-11-01 00:00:00 至 To 2025-11-30 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
采用平衡区组随机化方式,通过R语言代码生成随机序列号,分别为1-76,选择固定的区组长度,区组间排列随机,受试者签署知情同意书并获得ID(001-076),术者从保管柜取出对应ID信封,术前当患者面开启,根据卡片指示准备器械。 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
A balanced block randomization method was employed. Using R code, a random sequence numbered 1-76 was generated with fixed block lengths and random block permutation. After subjects provided informed consent and were assigned an ID (001-076), the surgeon retrieved the corresponding sealed envelope from a secure cabinet. This envelope was opened in the presence of the patient prior to surgery, and instruments were prepared according to the instructions on the card contained within. |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
随机化过程由一名对患者数据不知情的医院工作人员进行。两组手术方案对患者及手术操作人员不设盲,因为两组手术方案差异明显以及术者需明确执行ACIC或单纯截骨术,技术操作无法掩盖。对结局评估者和数据分析师设盲,影像学及功能评分员不接触手术记录及患者的日常管理。数据分析师使用编码分组数据(如A组/B组),分析完成后揭晓对应干预。患者发生严重不良事件(SAE)及法律或监管机构要求时揭盲。 |
|
Blinding: |
The randomization process was performed by a hospital staff member who had no access to patient data. Blinding of the patients and surgical team was not feasible due to the distinct differences between the two surgical protocols and the specific technical requirements for performing either ACIC or osteotomy alone. However, outcome assessors and data analysts were blinded to the group assignments. The imaging and functional score assessors were not permitted to access surgical records or the patients' routine clinical management data. Data analysts worked with coded group data (e.g., Group A/Group B), and the group identities were only revealed after the primary analysis was completed. Unblinding was permitted only in cases of serious adverse events (SAEs) or if required by legal or regulatory authorities. |
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
否No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
no |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
no |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
no |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
no |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |